Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

por Voloshyna, N, Havrdová, E, Hutchinson, M, Nehrych, T, You, X, Belachew, S, Hotermans, C, Paes, D
Publicado 2015

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A m...

por Seynaeve, C., Schuller, J., Buser, K., Porteder, H., Van Belle, S., Sevelda, P., Christmann, D., Schmidt, M., Kitchener, H., Paes, D.
Publicado 1992